Macquarie Group’s Lipocine LPCN Stock Holding History

Macquarie Group’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-135	Closed	-$3K	–	1870
2018 Q4	$3K	Buy	+135	New	+$3.13K	﹤0.01%	2159

Other funds holding LPCN

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SIM

Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Macquarie Group's LPCN Position: Q1 2019 in Review

Macquarie Group sold out of Lipocine (LPCN) in Q1 2019, closing a stake of 135 shares — an estimated $3K sold.

Macquarie Group first reported a position in LPCN in Q4 2018 and held it in 1 quarter. The position peaked at $3K in Q4 2018. 31 funds tracked by Wall St. Rank hold LPCN as of Q1 2019.

Macquarie Group reported no remaining Lipocine position as of Q1 2019 after selling out during the quarter.
Macquarie Group sold 135 Lipocine shares in Q1 2019, an estimated $3K.
Macquarie Group first reported a position in Lipocine in Q4 2018 and held it in 1 quarter.
Macquarie Group's Lipocine position peaked at $3K in Q4 2018.
31 funds tracked by Wall St. Rank held Lipocine as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.